Lucid diagnostics selects veeva vault cdms for esoguard® study

Vault cdms to manage clinical data for trial involving barrett's esophagus and esophageal adenocarcinoma patients pleasanton, calif., may 4, 2022 /prnewswire/ -- veeva systems (nyse: veev) today announced that lucid diagnostics inc. (nasdaq: lucd), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of pavmed inc. (nasdaq: pavm, pavmz), has selected veeva vault cdms to provide electronic data capture (edc), coding, and data cleaning in their upcoming study for esoguard in patients undergoing standard of care screening for, and management of, barrett's esophagus or esophageal adenocarcinoma.
VEEV Ratings Summary
VEEV Quant Ranking